• Most Popular
  • Most Shared

Zeltia says to seek Yondelis ovarian approval in Q4

Thu Aug 7, 2008 5:45am EDT

Stocks

   

MADRID, Aug 7 (Reuters) - Spanish pharmaceutical firm Zeltia (ZEL.MC) said on Thursday it would seek regulatory approval for the use of its Yondelis drug in the treatment of ovarian cancer after receiving positive results from Phase III trials.

Stocks  |  Regulatory News  |  Global Markets

It would seek approval in the last quarter of this year, it said.

The firm's stock rose 7.9 percent on Thursday and has now risen 23 percent in the last five sessions on hopes for the adoption of the drug to treat ovarian cancer. It is already used to fight soft-tissue sarcomas. (Reporting by Judy MacInnes; writing by Ben Harding)

Stocks
Regulatory News
Global Markets


More from Reuters

Photo

House prices stall, consumer confidence up

NEW YORK (Reuters) - U.S. consumer confidence rose to a three-month high in December, while prices in the hard-hit housing sector stalled in October, breaking a five-month string of gains.

» More Top News
An employee swipes a customer's credit card through the card reader at a restaurant in Tokyo February 19, 2005.REUTERS/Issei Kato

Taking a swipe at credit cards

New legislation meant to protect consumers could be a "game changer" for the industry -- and not in a good way.  Full Article 

Economy
A traveller lifts her arms as she stands in the new security scan at Schiphol airport, Netherlands, May 15, 2007.REUTERS/Jerry Lampen

Are you ok getting "naked"?

Full-body scanners can detect weapons under clothing but also expose passengers to operators. Should security trump privacy?  Full Article | Video 

U.S.